Clinical Findings

Has ProSure been clinically tested?

Yes. Clinical studies among people with various types of cancer, including pancreatic, lung, esophageal, head and neck, and colorectal cancer, showed that drinking ProSure daily as part of an overall cancer care program can help improve appetite and dietary intake, promote weight gain, help build muscle, and is associated with improved physical activity, improved quality of life, increased strength in those who gained weight and reduced treatment interruptions/toxicities.

Why were the first clinical trials conducted in people with pancreatic cancer?

People who have this type of cancer experienced rapid, severe weight loss, often losing 15% of their body weight by the time of diagnosis. ProSure was shown to benefit people with pancreatic cancer. Subsequent studies, as noted above, have shown that people with other types of cancer also benefit when ProSure is part of their overall cancer care.

Can ProSure be used by people with cancer undergoing radiotherapy and/or chemotherapy?

Yes. In fact, a new study8 shows benefits for people with lung cancer who were undergoing chemotherapy when ProSure was part of their cancer care plan. Maintaining or improving nutritional status and weight are key factors in being able to tolerate and continue therapy. Check with your healthcare professional to see if ProSure is right for you. Use ProSure under healthcare professional supervision.

Clinical studies that prove ProSure may reduce cachexia

1. Barber M, Ross J, Voss A, et al. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Can. 1999;81:80-86.

2. Barber MD, Fearon KC, Tisdale MJ, McMillan DC, Ross JA. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutr Cancer. 2001;40:118-124.

3. Barber MD, McMillan DC, Preston T, et al. Metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish-oil-enriched nutritional supplement. Clin Sci. 2000;98:389-399.

4. Fearon K, von Meyenfeldt M, Moses A, van Geenen R, et al. Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut. 2003;52:1479-1486.

5. Bauer JD, Capra S. Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy—a pilot study. Support Care Cancer. Apr 2005;13(4):270-274.

6. Jatoi A, Rowland K, Loprizini C, Sloan J, et al., North Central Cancer Treatment Group. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol. 2004;22(12):2469-2476.

7. de Luis DA, Izaola O, Aller R, Cuellar L, Terroba MC. A randomized clinical trial with oral Immunonutrition (omega3-enhanced formula vs. arginine-enhanced formula) in ambulatory head and neck cancer patients. Ann Nutr Metab. Mar-Apr 2005;49(2):95-99.

8. van der Meij BS, Langius JA, Smit EF, et al. Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. J Nutr. Oct 2010;140(10):1774-1780.

9. Guarcello M, Riso S, Buosi R, D’Andrea F. EPA-enriched oral nutritional support in patients with lung cancer: Effects on nutritional status and quality of life. Nutr Ther & Metab. 2007;25(1):25-30

10. Read J, Beale P, Volker D, Smith N, Childs A, Clark S. Nutrition intervention using an eicosapentaenoic acid-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status. Support Care Cancer. 2007;15:301-307.

11. Capuano G, Pavese I, Satta F. Critical considerations on the use of a protein and energy dense omega-3 enriched sip feed in cancer patients. Rivista Italiana di Nutrizione Parenterale ed Enterale. 2005;23:43-46.

12. Weed HG, Ferguson ML, Gaff RL, Hustead DS, Nelson JL, Voss AC. Lean body mass gain in patients with head and neck squamous cell cancer treated perioperatively with a protein- and energy-dense nutritional supplement containing eicosapentaenoic acid. Head Neck. Jul 2011;33(7):1027-1033.

13. Trabal J, Leyes P, Forga M, Maurel J. Potential usefulness of an EPA-enriched nutritional supplement on chemotherapy tolerability in cancer patients without overt malnutrition. Nutr Hosp. Oct 2010;25(5):736-740.

14. Voss A, Scripekova A, Csoka T, Kecskes I, Vanek P. Effect of a protein and energy dense eicosapentaenoic containing oral supplement on loss of weight and inflammation in cancer cachexia. JPEN J Parenter Enteral Nutr. 2012;36(1):A136.

15. Ryan AM, Reynolds JV, Healy L, et al. Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial. Ann Surg. Mar 2009;249(3):355-363.

16. Sanchez-Lara K, Turcott J, Juarez E, et al. Randomized trial effect of an oral nutritional supplement with eicosapentaenoic acid on nutritional and inflammatory parameters, response and toxicity to chemotherapy, quality of life, and survival in treatment-naive patients with advanced non-small lung cancer. J Clin Oncol. 2012;30:suppl; abstr e19594.

17. Davidson W, Ash S, Capra S, Bauer J, On behalf of the Cancer Cachexia Study Group. Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr. 2004;23:239-247.

18. Moses A, Slater C, Preston T, Barber M, Fearon K. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Can. 2004;90:996-1002.

19. Barber M, Ross J, Preston T, Shenkin A, Fearon K. Fish oil-enriched nutritional supplement attenuates progression of the acute-phase response in weight-losing patients with advanced pancreatic cancer. J Nutr. 1999;129:1120-1125.

20. Garcia-Almeida JM, Murri-Pierri M, Lupiáñez-Pérez Y, et al. Effect of oral supplementation enriched with omega-3 fatty acids in inflammatory parameters and oxidative stress in patients with otolaryngologist cancer treated with radiotherapy. Clin Nutr Suppl. 2010;5(2):140.